For almost everyone at Bigfoot Biomedical, diabetes is personal. "Our solution is something my family desperately needs," says CEO Jeffrey Brewer about the company's all-out efforts to bring to market a disruptive, new technology to make life with diabetes easier and safer.
Western Alliance's Bridge Bank saw this purpose as an intangible asset for this emerging medical device company. "This bank is a true partner. We had a number of proposals, but Bridge Bank went the extra mile to give us comfort that this would be a relationship vs. a transaction, and that is exactly how it's been," adds Brewer.
Today, dosing insulin is complicated and cumbersome, requiring multiple prescriptions and devices, and can be prone to error. Now Bigfoot is making big strides, heading toward pivotal trials for its breakthrough solutions – each part of an overarching ecosystem designed to deliver insulin in a safer, more user-friendly way for a broader range of people living with insulin-requiring diabetes.
"We know our clients and this market, and what's motivating this management team to innovate and persevere just adds to Bigfoot's immense opportunity." Rob Lake, Head of Life Sciences at Bridge Bank.